APY29 is an allosteric modulator of IRE1α; inhibits IRE1α autophosphorylation (IC50 = 280 nM) and activates IRE1α RNase activity.

AR231453 is a potent and selective small molecule agonist of GPR119 that enhances glucose-dependent insulin secretion and glucagon-like peptide 1 (GLP-1) release; Antidiabetic agent.

AR7 is a retinoic acid receptor α (RARα) antagonist.

ARA-290 (Cibinetide) is a non-erythropoietic erythropoietin (EPO) derivative.

Ara-G (9-β-D-Arabinofuranosyl guanine) is an inducer of apoptosis, inhibitor of DNA synthesis, an antimetabolite, and antineoplastic.

Umifenovir is currently being investigated as a potential treatment and prophylactic agent for COVID-19 caused by SARS-CoV2 infections in combination with both currently available and investigational HIV therapies. Arbidol hydrochloride (Umifenovir hydroc

Arctigenin is an extract from A. lappa, a burdock plant traditionally used in Japanese Kampo medicine for its antioxidant, anti-inflammatory,

Arctiin, a plant lignan that can be extracted from the Arctium lappa (burdock) seeds, is a possible environmental endocrine disruptor compounds and have been shown to influence sex hormone metabolism as well as protein synthesis, steroid biosynthesis.

Argatroban

Argatroban monohydrate is a direct, selective thrombin inhibitor.

Arg-Gly-Asp-Ser(RGDS peptide) is an integrin binding sequence that inhibits integrin receptor function; decreases systemic inflammation via inhibition of collagen-triggered activation of leukocytes and attenuates expression of inflammatory cytokines, iNOS

Arglabin is a sesquiterpene gamma-lactone is isolated from Artemisia glabella; anticancer natural compound.

ARM390 is a non-peptidic, low-internalizing δ-selective opioid receptor agonist.

ARN2966 is a potent post-transcriptional modulator of APP expression; reduces expression of APP with resultant lower production of Aβ.

ARN-3236 is potent, orally active and selective SIK2 inhibitor. ARN-3236 inhibited the growth of 10 ovarian cancer cell lines at an IC50 of 0.8 to 2.6 μmol/L.

ARN-509 is a selective and competitive androgen receptor inhibitor with IC50 of 16 nM, useful for prostate cancer treatment.

ARQ 092 is an oral activie, potent and selective AKT inhibitor with IC50 values: 5.0 nM (AKT1); 4.5 nM (AKT2); 16 nM (AKT3).

ARQ 621 is an allosteric, and selective Eg5 mitotic motor protein inhibitor. Phase 1.

ARQ-531 is a potent, reversible, orally available inhibitor of both wild type and C481S-mutant BTK kinase with IC50 of 0.85 and 0.39 nM,

ARRY-520 is a synthetic, small molecule kinesin spindle protein (KSP) inhibitor with IC50 of 6 nM.

ARS-1323 is a novel inhibitor of mutant K-ras G12C.

ARS-1620 is a covalent compound with high potency and selectivity for KRAS-G12C.